Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INVOPE: Intranasal Sufentanil for Severe Sickle Cell Vaso-occlusive Pain Crisis in Children
2023-504847-15-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sufentanil in sickle cell disease (SCD) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Proportion of children relieved at 30 minutes after intranasal spray. Planned start Nov 2023; status: authorised.
02
Drugs
sufentanil
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2023-504847-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504847-15-00.